{"id":1810,"date":"2004-06-01T12:04:00","date_gmt":"2004-06-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/schwere-cholestatische-hepatitis-durch-einnahme-von-pyritinol"},"modified":"2004-06-01T12:04:00","modified_gmt":"2004-06-01T10:04:00","slug":"schwere-cholestatische-hepatitis-durch-einnahme-von-pyritinol","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/schwere-cholestatische-hepatitis-durch-einnahme-von-pyritinol","title":{"rendered":"Schwere cholestatische Hepatitis durch Einnahme von Pyritinol"},"content":{"rendered":"<p>Im Brit. Med. J. (1) berichten V. Maria et al. aus Lissabon unter der Rubrik \u201eLesson of the week\u201d \u00fcber sechs junge (18-41 Jahre) Patienten (5 Frauen), die zum Zweck des \u201eMemory improvement\u201d zwei- bis dreimal 200 mg Pyritinol\/d (Encephabol\u00ae) f\u00fcnf Tage bis einen Monat lang eingenommen hatten. Danach traten \u00dcbelkeit mit oder ohne Erbrechen, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Brit. Med. J. (1) berichten V. Maria et al. aus Lissabon unter der Rubrik \u201eLesson of the week\u201d \u00fcber sechs junge (18-41 Jahre) Patienten (5 Frauen), die zum Zweck des \u201eMemory improvement\u201d zwei- bis dreimal 200 mg Pyritinol\/d (Encephabol\u00ae) f\u00fcnf Tage bis einen Monat lang eingenommen hatten. Danach traten \u00dcbelkeit mit oder ohne Erbrechen, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3425,2564,3991],"class_list":["post-1810","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-cholestatische-hepatitis","tag-hepatitis","tag-pyritinol"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1810"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1810\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}